Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2011

View Archived Issues

Findings reported from REFLEX and MOSAIC trials of IFN-beta1a

Final results available of first OvaSave trial in Crohn's disease

Two PentaStaph vaccine components are immunogenic in phase I/II testing

Study compares Merck & Co. 15-valent pneumococcal conjugate vaccine to Prevnar

Roche presents highlights of third quarter 2011

Shigamabs well tolerated to date in phase II trial

Shire reviews developments of third quarter 2011

XTL Biopharmaceuticals set to acquire technology being developed for cartilage-related diseases

OXiGENE discloses final data from FALCON study

Randomization begins in phase IIb study of Jennerex's JX-594 in advanced liver cancer

Pfizer returns worldwide rights to TNF-alpha-targeted Nanobodies

Novel radioprotective agents divulged by Peter MacCallum Cancer Centre

Merck & Co. discloses new fatty-acid amide hydrolase 1 inhibitors

CancerTYPE ID test can improve outcome of patients with cancer

Verseon presents novel thrombin inhibitors

Rexahn Pharmaceuticals presents phase IIb data on Serdaxin

New GPR119 receptor agonists claimed

RegeneRx announces phase II RGN-259 data

FDA finds no link between ADHD medications and adverse cardiovascular events

Arena Pharmaceuticals patents new molecules for type 2 diabetes and obesity

Ongoing phase IIa trial in hepatitis C adds four treatment arms

Pfizer files application in Japan seeking approval for new indication of Sutent

FDA approves Bayer's Xarelto for new indication

FDA provides update on safety review of TNF blockers

SYGNIS' AXIS 2 trial advances

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...